prompt stringlengths 2.68k 6.44k | completion stringlengths 264 4.65k |
|---|---|
<DOCUMENT>Protocol: 2014-0443 Version 2.1 Version Date: 11 April 2016</DOCUMENT>
<DOCUMENT>Pregnancy Testj Xc,n Xc X X X X X X X X X
Urinalysis X n X
Chemistry Panel Xc,n Xc X X X X X X X X X
CBC, Differential, Platelets Xc,n Xc X X X X X X X X X
Coagula tion X n X
Serum Virology (HIV, HB... | Step 1: Note c explicitly states that if an evaluation (assessment) is performed within the 24 hours immediately preceding the first dosing of the treatment, then the measurement from that assessment is used as the baseline evaluation.
Step 2: Since the assessment performed within that 24-hour window is considered suf... |
<DOCUMENT>Study site personnel should record all study drugs admin istered during this trial on the drug -
dispensing log. This log may also be reviewed by the research pharmacist. The drug dispensing log
will contain the following informati on:
• patient study identification number
• date(s) of study drug admini... | Step 1: Review the provided context for any sections that talk specifically about the drug dispensing log.
Step 2: Identify the part that discusses what should be recorded on that log.
Step 3: Note that the text explicitly states that the drug dispensing log "will contain the following information:" followed by a l... |
<DOCUMENT>using popul ation PK and/or PK -pharmacodynamic methods.
4.2.4.3 Immunogenicity - ADAs
A summary will be provi ded of number and percentage of patients who develop detectable
ADAs. The immunogenicit y titer and neutralizing ADA data will be listed for samples
confirmed posit ive for the presence of ant i-d... | Step 1: Recognize that the study is set up to assess immunogenicity by summarizing ADA (antidrug antibody) data separately for each therapeutic agent. The document specifies separate summaries for anti‐durvalumab and anti‐tremelimumab antibodies.
Step 2: Understand the definition of evaluability. When summarizing immu... |
<DOCUMENT>20 Donia M, Junker N, Ellebaek E, et al. Characterization and
comparison of ‘Standard’ and ‘young’ tumour- infiltrating
lymphocytes for adoptive cell therapy at a Danish Translational
research institution. Scand J Immunol 2012;75:157–67.
21 Andersen R, Borch TH, Draghi A, et al. T cells isolated from pat... | Step 1: Identify the Number of Cases
- The text states that out of 540,824 military personnel vaccinated, 67 developed symptomatic myopericarditis.
Step 2: Identify the Percentage of ECG Abnormalities
- Among the 61 ECGs that were reviewed, an identifiable abnormality was found in 46 of them.
- To calculate the percen... |
<DOCUMENT>Mobilized Leukapheresis
CBC w/ differential , comprehensive or basic metabolic panel
(per institutional standard) , T4/T8 ratio
β-HCG pregnancy test
Infectious disease testing to include, at a minimum,
HIV, Hepatitis B, Hepatitis C & CMV
Oral tums if standard of care
Re-MATC H Protoc... | Step 1: The paired analysis compared bone marrow samples before and after vaccination from the same patients.
Step 2: The study found that in the majority of patients, there was a striking and significant reduction in the numbers of clonal tumor idiotype-expressing B cells post-vaccine.
Step 3: In contrast, the clona... |
<DOCUMENT>- BCM is the lead site of this multicenter trial, or ,
- the industry sponsor has instructed the BCM PI to register the trial, or ,
- registration of this trail is required as a term and condition of the reward by the funding agency .
ClinicalT rials.gov Identifier:
NCT
Section B: Ex... | Step 1: Read the section of the study protocol that addresses the washout period for subjects who are on anti-androgen therapy.
Step 2: Identify the stated requirement for the washout period, which is 6 weeks for subjects on anti-androgens.
Step 3: Notice the specific adjustment mentioned for subjects taking flutam... |
<DOCUMENT>were determined by ELISpot assay of 14 days in vitro stimulated peripheral blood mononuclear cells as outlined in the Methods
section. Values are shown for the six patients with immune responses to either or both peptides. Time points with data that meet criteria for an immune response to pBCAR3 or pIRS2 are... | Step 1: Review the context provided. The text states that all patients will return to the NIH Clinical Center for their second follow-up evaluation one month (± 5 days) after the first follow-up evaluation.
Step 2: Look at the overall follow-up schedule. After the first follow-up evaluation, subsequent follow-up evalu... |
<DOCUMENT>and the results of other assessments. All available images collected during the trial period will be
considered. The most appropriate measures to evaluate the tumor status of a subject should be
used. The measure(s) to be chosen for sequential evaluation during the trial have to correspond to
the measures ... | Step 1: The text states that before stopping treatment, any progression observed by RECIST 1.1 must be confirmed with an imaging scan within 4 to 6 weeks after the initial progression diagnosis. This confirmation ensures that the progression is real and sustained.
Step 2: The protocol allows for treatment to be contin... |
<DOCUMENT>adverse events (TRAEs) included injection site reactions, skin induration, and pruritus occurred at a frequency of 43.8% to 62.5% across studies, and were Grade 1/ Grade 2 in
severity, consistent with the fact that Montanide (which is co-administered with galinpepimut-S) is a known irritant. All TRAEs observ... | Step 1: Identify the TRAEs associated with galinpepimut-S when administered with Montanide. The adverse events reported include injection site reactions, skin induration, and pruritus.
Step 2: Determine the severity grading for these adverse events. They were reported as Grade 1 and Grade 2 in severity, which are cons... |
<DOCUMENT>cell receptors were significantly decreased while expression of inhibitory receptors were increased in both
peripheral blood and breast tumor infiltrating NK cells; and stroma- derived inhibitory f actors particularly
TGF- β were involved in driving the impaired NK cell activity. Additionally, increased in... | Step 1: Immediately stop the nivolumab infusion when Grade 2 symptoms develop.
Step 2: Begin supportive care with an IV infusion of normal saline.
Step 3: Administer symptomatic treatment—specifically, give diphenhydramine 50 mg IV (or an equivalent antihistamine) and/or paracetamol (acetaminophen) in a dose of 325 t... |
<DOCUMENT>All TEAEs details will be listed with a separate listing for pre -treatment AEs.
Separate listing of all serious TE AEs and pre- treatment SAEs will also be presented.
5.3 Deaths
The total number and percentage of patients who died whilst on the study will be
summarised and by cause of death (due t... | Step 1: For each clinical laboratory parameter, first identify the baseline value. This is defined as the last scheduled or unscheduled value collected before the first dose of the IMP (Investigational Medicinal Product).
Step 2: Obtain the observed value measured at a scheduled visit after the baseline assessment.
S... |
<DOCUMENT>peptide-specific cytotoxicity. Importantly, T-cells stimulated with the new synthetic peptides
cross-reacted with the native WT1 peptide sequence and were able to destroy HLA -matched
CML blasts (Pinilla-Ibarz J et al, 2000;). This validates the expression and possibility of killing tumors in this system. O... | Step 1: The context provides that the total exposure to WT1 peptide in the myeloid group "ranged from 28 to 295 days."
Step 2: From this statement, we identify that the minimum exposure reported was 28 days and the maximum exposure was 295 days.
Step 3: It is also reported that the median exposure was 144.5 days.
<... |
<DOCUMENT>Both neoantigen-encoding genetic vaccines are administered intramuscularly using one prime with GAd-PEV and three boosts with
MVA –PEV in combination with the licensed programmed death receptor-1 (PD-1)-blocking antibody pembrolizumab in patients. Thefirst vaccination with GAd occurs on the day of the 4th admi... | Step 1: The text clearly states that… "six patients were treated at dose level 2" after dose level 1 saw toxicities in the first 3 patients.
Step 2: It then details the composition of the treatment at dose level 2. The treatment consisted of two specific cell counts: 5x10^8 colon cancer cells and 2x10^8 GM-CSF-produci... |
<DOCUMENT>Protocol: HERCEPTIN® + E75/GM-CSF Version 3.1 ML25749 05 March 2017 the analysis. The statistical validity of the survival analysis across the trials has been questioned because mortality was not the primary endpoint, and only 1 of the 4 trials achieved a significant result when analyzed based on the ... | Step 1: The text states that the first vaccination with the GAd-PEV vaccine is administered on the day of the 4th pembrolizumab infusion, which is scheduled to take place at week 10.
Step 2: After the initial GAd vaccination, the MVA-PEV boosts are scheduled as three separate doses. They are given every 3 weeks, with ... |
<DOCUMENT>drug supplies to the site. This approval document must refer to the study by exact protocol title and protocol version number/date and must identify the documents reviewed and the date of review. Protocol modifications or changes may not be initiated without prior written IRB/IEC approval except when necessa... | Step 1: The protocol requires that every adverse event (AE) reported in the study must have its relationship to the study product assessed.
Step 2: Two possible relationship assessments are provided for each AE: "Related" or "Not Related."
Step 3: The protocol defines a "Related" adverse event as one for which there ... |
<DOCUMENT>or a cumulated total of 278 deaths (both counts excluding the 38 patients
enrolled before protocol 4.0) is reached.
Step-1 analysis was reviewed by the independent data monitoring committee
(IDMC) i n March 2020 . Step-1 data show ed that the pre defined thresholds of 12
months -OS rate in OSE2101 arm wa... | Step 1: Read the provided passage. It states that "stopping all components of VBIR-2 is recommended at least 7 days prior to surgery."
Step 2: This recommendation is made to minimize the risk of impaired wound healing and bleeding.
Step 3: Therefore, based on the passage, the minimum time required to stop all compon... |
<DOCUMENT>site is possible, please instruct the subject to place a measuring tool (bulk supplies
provided to the site) next to the injection site reaction in the picture, if feasible. The
photograph may be provided to the clinic upon the next visit as a hard copy or electronic jpg image. Please instruct the partici... | Step 1: The guideline states that measurable lesions on CT scans are defined with the assumption that the CT slice thickness is 5 mm or less.
Step 2: When CT scans are performed with a slice thickness greater than 5 mm, the guideline makes an adjustment: it specifies that the minimum measurable lesion should be twice... |
<DOCUMENT>the paradigm of Stage II disease, with definitive chemoradiotherapy or resection plus adjuvant
treatment. Consequently, while the prognosis for Stage I patients is better than Stage II and III,
there is a need for de-intensification of treatment in Stage I T1-2 N1 disease.
In this clinical trial, we are st... | Step 1: Examining the Day 28 (±3 days) schedule, we identify that the evaluations performed at that visit include:
– Taking an updated medical history along with a focused physical exam that includes checking vital signs.
– Reviewing any medications the patient is taking.
– Assessing the patient’s performance status... |
<DOCUMENT>will categorize the event by organ system, relationship to treatment, its grade of severity, and resolution.
The PI will periodically review the collective adverse events with the intention of identifying any trends or
patterns in toxicity on a monthly basis . If any such trends are identified, depending o... | Step 1: Identify the relevant exclusion criterion in the provided text.
The text states in section 3.2.1: "Patients who have had cytotoxic chemotherapy, radiotherapy, IFN, immunosuppressive therapy, or steroids within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before entering the study..."
Step 2: List the ther... |
<DOCUMENT>approximately 4-8 oz. of warm water . The lid is then applied to seal the cup and shaken vigorously to
dissolve the powder. The liquid preparation is to be consumed within 15 minutes. After the initial Table 3. Quantitative Composition of the PSK® Clinical Drug Product in Each Unit Dose Pouch
Componen... | Step 1: The study explicitly stated that one limitation was the small sample size. This means that the number of patients enrolled in the trial was limited, which may affect the robustness and generalizability of the findings.
Step 2: The study acknowledged the absence of a control arm. This absence prevented the rese... |
<DOCUMENT>vaccinia, expected local reactions include the appearance of a clear cut pustule 6-8 days following
vaccination or the development of an area of definite induration around a central lesion that may
be an ulcer or scab 6-8 days following vaccination. The response to re-vaccination depends on the
degree of r... | To determine how the overall number of inferred ligand-receptor interactions changed after vaccination, we start by reviewing the methodology described. The study used the CellChat software to analyze cell-cell communications using aggregate single-cell RNA sequencing (sc-RNAseq) data from bone marrow samples collected... |
<DOCUMENT>expression and enzymatic activity correlates strongly with prognosis in multiple cancers
[Liu 2009]. The expression of IDO1 correlates w ith more extensive disease and is an
independent prognostic factor for reduced overall survival. In one study, moderate to strong cytoplasmic IDO expression was present ... | Step 1: Recognize Digoxin's Dual Role
Digoxin is classically known for its positive inotropic (contractility enhancing) effect in chronic heart failure. However, it also exerts neurohormonal-modulating effects that are independent of its inotropic action. These effects include the modulation of autonomic function.
Ste... |
<DOCUMENT> Histologic al diagnosis of a solid malignancy
Treatment with monotherapy immune checkpoint inhibitor (ICI) against
Programmed Death 1 (PD1) or its ligand PD -L1 (in curative or non -curative
setting)
Last ICI administration within 3 months of vaccination
Addition al criteria for co hort C: ... | Step 1: For Grade 4 creatinine elevations (i.e., creatinine increased >6× the upper limit of normal), the protocol mandates that you permanently discontinue study treatment. Additionally, you must:
• Monitor the patient’s creatinine levels daily.
• Initiate corticosteroid therapy at 1.0 to 2.0 mg/kg/day prednisone (or ... |
<DOCUMENT>• Day 1 will be the first day of TG01 treatment. GM -CSF/TG01 will be
administered on Days 1, 3, 5, 8 and 15 and then 2- weekly until the end
of chemotherapy treatment.
• Chemotherapy will commence at the same time as GM-CSF/TG01 and 6
cycles of chemotherapy will be given.
• DTH skin test injections... | Step 1: Identify what coded linked human data refers to. In this context, the data consists of human subjects' information that has been coded for privacy but still allows for linking to original subjects under controlled conditions.
Step 2: Review the Human Data Sharing Plan. The plan specifies several avenues for sh... |
<DOCUMENT>control Arm B (docetaxel or pemetrexed) when 278 events observed ; due to early
study discontinuation (219 patients included instead of 363 patients), statistical
hypothesis was revised with a comparison between experime ntal Arm A and
control Arm B in the PoI (refer statistical methodology section)
Se... | Step-by-step reasoning:
1. The provided context clearly lists the key information regarding the QLQ-C30 assessment in Step 1.
2. It specifically states that the “Global health status/QoL” score was based on questions 29 and 30.
3. Question 29 asks: "How would you rate your overall health during the past week?"
4. Ques... |
<DOCUMENT>D
uration of tr eatment will be calculated as date of last dose – date of first dose + 1.
D
osing details will be presented in listings for all subjects
7.3.
Post-Vaccination Prostate Cancer Therapy
Po st-vaccination prostate cancer therapy will be collected and the number of subjects receiving
therapy... | Step 1: The study divided the 28 cancer patients based on whether they had received radiofrequency ablation (RFA) treatment within the 6 months preceding the neoantigen vaccine administration.
Step 2: Two cohorts were formed from this stratification. One cohort (Cohort 1) consisted of patients who had received RFA wit... |
<DOCUMENT>validated PK analysis program. Actual times will be used for the analyses.
Endpoint Statistical Analysis Methods
Cmax, AUC(0-T), AUC(TAU), Ctau, CLT,
Css-avg, AI_AUC, AI_Cmax, AI-Ctau,
THALFeff_AUC, THALFeff_CmaxSummary statistics: geometric means and coefficients
of variation
Tmax Summary statistics: medi... | Step 1: The protocol specifies that Ctrough values are used to assess whether steady‐state conditions have been achieved in subjects undergoing treatment.
Step 2: These Ctrough values (concentrations measured at the end of a dosing interval) are summarized using descriptive statistics—specifically the geometric mean a... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 6